PL1781321T3 - Sposób leczenia raka zawierający antagonistę VEGF-B - Google Patents

Sposób leczenia raka zawierający antagonistę VEGF-B

Info

Publication number
PL1781321T3
PL1781321T3 PL05764158T PL05764158T PL1781321T3 PL 1781321 T3 PL1781321 T3 PL 1781321T3 PL 05764158 T PL05764158 T PL 05764158T PL 05764158 T PL05764158 T PL 05764158T PL 1781321 T3 PL1781321 T3 PL 1781321T3
Authority
PL
Poland
Prior art keywords
vegf
antagonist
treating cancer
cancer
treating
Prior art date
Application number
PL05764158T
Other languages
English (en)
Inventor
Andrew Nash
Felicity Meredith Dunlop
Manuel Baca
Louis Jerry Fabri
Pierre David Scotney
Original Assignee
Zenyth Operations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35786817&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1781321(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zenyth Operations Pty Ltd filed Critical Zenyth Operations Pty Ltd
Publication of PL1781321T3 publication Critical patent/PL1781321T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL05764158T 2004-08-02 2005-08-02 Sposób leczenia raka zawierający antagonistę VEGF-B PL1781321T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US59815904P 2004-08-02 2004-08-02
US63444404P 2004-12-09 2004-12-09
EP05764158.1A EP1781321B1 (en) 2004-08-02 2005-08-02 A method of treating cancer comprising a vegf-b antagonist
PCT/AU2005/001152 WO2006012688A1 (en) 2004-08-02 2005-08-02 A method of treating cancer comprising a vegf-b antagonist

Publications (1)

Publication Number Publication Date
PL1781321T3 true PL1781321T3 (pl) 2014-07-31

Family

ID=35786817

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05764158T PL1781321T3 (pl) 2004-08-02 2005-08-02 Sposób leczenia raka zawierający antagonistę VEGF-B

Country Status (10)

Country Link
US (2) US8822644B2 (pl)
EP (2) EP1781321B1 (pl)
JP (3) JP5014130B2 (pl)
AU (1) AU2005269265B2 (pl)
CA (1) CA2575901C (pl)
DK (2) DK1781321T3 (pl)
ES (1) ES2456943T3 (pl)
HK (1) HK1103654A1 (pl)
PL (1) PL1781321T3 (pl)
WO (1) WO2006012688A1 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ599464A (en) 2005-02-03 2014-03-28 Topotarget Uk Ltd Combination therapies using hdac inhibitors
CN102579417B (zh) 2005-05-13 2014-11-26 托波塔吉特英国有限公司 Hdac抑制剂的药物制剂
AU2006313517B2 (en) 2005-11-10 2013-06-27 Topotarget Uk Limited Histone deacetylase (HDAC) inhibitors (PXD101) for the treatment of cancer alone or in combination with chemotherapeutic agent
MX2010003230A (es) 2007-09-25 2010-04-07 Topotarget Uk Ltd Metodos para la sintesis de ciertos compuestos de acido hidroxamico.
US8349322B2 (en) 2008-06-25 2013-01-08 ESBATech, an Alcon Biomedical Research Unit, LLC Stable and soluble antibodies inhibiting VEGF
DK2668210T3 (da) 2011-01-26 2020-08-24 Celldex Therapeutics Inc Anti-kit antistoffer og anvendelser deraf
WO2012104227A1 (en) * 2011-02-02 2012-08-09 Glaxo Group Limited Novel antigen binding proteins
US20130085095A1 (en) * 2011-09-29 2013-04-04 Trustees Of Boston University Protein complementation regulators
CA2871417C (en) * 2012-04-23 2021-08-31 Genefrontier Corporation Anti-human cd69 antibody, and use thereof for medical purposes
CA2880007C (en) 2012-07-25 2021-12-28 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
US20150246117A1 (en) 2012-09-24 2015-09-03 Ulf Eriksson Treatment of type 2 diabetes and related conditions
CN105873608A (zh) 2013-11-28 2016-08-17 杰特有限公司 治疗肾病的方法
AU2014366837B2 (en) * 2013-12-18 2020-06-25 B-Creative Sweden Ab Method of treating wounds
CN113908269A (zh) 2014-05-23 2022-01-11 塞尔德克斯医疗公司 嗜酸性粒细胞或肥大细胞相关病症的治疗
EP3220952B1 (en) * 2014-11-17 2021-04-21 CSL Limited Method of treating or preventing stroke
EP3445450A4 (en) * 2016-04-21 2020-01-08 CSL Limited METHOD FOR TREATING OR PREVENTING LIVER DISEASES
WO2022133169A1 (en) 2020-12-18 2022-06-23 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
WO2023115112A1 (en) * 2021-12-20 2023-06-29 CSL Innovation Pty Ltd Protein formulations and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000A (en) * 1845-04-16 Combined lock and latch
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
WO1986005807A1 (en) 1985-04-01 1986-10-09 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5359051A (en) 1990-01-11 1994-10-25 Isis Pharmaceuticals Compounds useful in the synthesis of nucleic acids capable of cleaning RNA
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5607918A (en) * 1995-03-01 1997-03-04 Ludwig Institute For Cancer Research Vascular endothelial growth factor-B and DNA coding therefor
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
US20040102389A1 (en) 1995-10-26 2004-05-27 Ribozyme Pharmaceuticals, Inc. Nucleic acid-mediated treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
US5916763A (en) * 1995-11-09 1999-06-29 The Regents Of The University Of California Promoter for VEGF receptor
US6482802B1 (en) * 1998-05-11 2002-11-19 Endowment For Research In Human Biology, Inc. Use of neomycin for treating angiogenesis-related diseases
AU4662400A (en) * 1999-04-26 2000-11-10 Helsinki University Licensing Ltd Role of vascular endothelial growth factor-b (vegf-b) in developing bones and uses thereof
US6942981B1 (en) * 1999-05-14 2005-09-13 Arbor Vita Corporation Method of determining interactions with PDZ-domain polypeptides
WO2003070910A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2003062788A2 (en) 2002-01-17 2003-07-31 Genetix Pharamaceuticals, Inc. Method for inhibiting angiogenesis
CA2429483A1 (en) 2002-05-17 2003-11-17 Amrad Operations Pty Ltd. Immunointeractive molecules
US20030232439A1 (en) * 2002-06-17 2003-12-18 Isis Pharmaceuticals Inc. Antisense modulation of VEGF-B expression
MX2007001589A (es) * 2004-08-09 2007-08-02 Alios Biopharma Inc Variantes de polipeptido resistentes a proteasa, hiperglicosiladas sinteticas, formulaciones orales y metodos para utilizar las mismas.

Also Published As

Publication number Publication date
JP5014130B2 (ja) 2012-08-29
EP2476427B1 (en) 2018-01-17
JP5662912B2 (ja) 2015-02-04
CA2575901A1 (en) 2006-02-09
ES2456943T3 (es) 2014-04-24
WO2006012688A1 (en) 2006-02-09
JP2008508325A (ja) 2008-03-21
US20080260729A1 (en) 2008-10-23
JP2012036189A (ja) 2012-02-23
JP2014224149A (ja) 2014-12-04
AU2005269265A1 (en) 2006-02-09
EP1781321A4 (en) 2009-11-18
EP2476427A2 (en) 2012-07-18
HK1103654A1 (en) 2007-12-28
DK2476427T3 (en) 2018-05-07
AU2005269265B2 (en) 2012-01-12
US20140363445A1 (en) 2014-12-11
US8822644B2 (en) 2014-09-02
CA2575901C (en) 2015-01-27
EP2476427A3 (en) 2012-10-03
EP1781321B1 (en) 2014-01-08
DK1781321T3 (da) 2014-04-14
EP1781321A1 (en) 2007-05-09

Similar Documents

Publication Publication Date Title
PL1781321T3 (pl) Sposób leczenia raka zawierający antagonistę VEGF-B
IL179139A0 (en) Method for treating multiple sclerosis
ZA200508427B (en) Methods for treating interleuking-6 related diseases
PL2302097T3 (pl) Metoda obróbki powierzchni
GB0416871D0 (en) Well characterisation method
GB0308731D0 (en) Method of radiotherapy
EP1732650A4 (en) COMPOSITION AND METHOD FOR CANCER TREATMENT
EP1755394A4 (en) METHOD OF TREATING CANCER
EP1734334A4 (en) EXPLOSION PROCESS
IL176919A0 (en) Methods and compositions for treating cancer
ZA200705059B (en) Cancer treatment method
EP1725237A4 (en) ANTI-ALCOHOLIC TREATMENT
EP1707914A4 (en) PROCESS FOR EXPLOSION TREATMENT
GB2435169B (en) Process for treating an underground formation
IL179323A0 (en) Cancer treatment method
GB0422004D0 (en) Method of deprotection
EP1742629A4 (en) METHOD FOR TREATING ALCOHOLISM
IL179359A0 (en) Cancer treatment method
GB2464421B (en) Method of forming tubing
EP1791969A4 (en) METHOD FOR THE TREATMENT OF CANCER
EP1809276A4 (en) PROCESSING PROCESS
GB0424005D0 (en) Method of coating
EP1802617A4 (en) CANCER TREATMENT METHOD
GB0413346D0 (en) Treating cancer
GB0426196D0 (en) Methods of treatment